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Abstract: 
Purpose of review – Adrenal masses are highly prevalent, found in 5% of the population. 
Differentiation of benign adrenocortical adenoma from adrenocortical carcinoma is currently 
hampered by the poor specificity and limited evidence base of imaging tests. This review 
summarizes the results of studies published to date on urine steroid metabolite profiling for 
distinguishing benign from malignant adrenal masses.  
Recent findings: Three studies have described cohorts of at least 100 patients with adrenal 
tumors showing significant differences between urinary steroid metabolite excretions according 
to the nature of the underlying lesion, suggesting significant value of steroid metabolite profiling 
as a highly accurate diagnostic test. 
Summary: Steroid profiling is emerging as a powerful novel diagnostic tool with a significant 
potential for improving the management for patients with adrenal tumors. While the current 
studies used gas chromatography-mass spectrometry for proof-of-concept, widespread use of 
the method in routine clinical care will depend on transferring the approach to high-throughput 
tandem mass spectrometry platforms. The use of computational data analysis in conjunction 
with urine steroid metabolite profiling, i.e. steroid metabolomics, adds accuracy and precision. 
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Introduction 
 
Adrenal masses are common, with a reported overall prevalence of at least 5% in the population 
1, 2. Prevalence increases with age, ranging between <0.5% in children and around 10% in 70-
year-old patients 3, 4. Most patients are diagnosed incidentally on cross-sectional abdominal 
imaging performed for indications other than suspected adrenal disease. In the United States 
alone, the number of computed tomography (CT) imaging performed quadrupled from 21 million 
per year in 1995 to more than 80 million per year in 2014 5. Increase in widespread use coupled 
with enhancement in the quality of cross-sectional imaging explains the growing numbers of 
patients newly diagnosed with an adrenal tumor requiring further diagnostic assessment.  
 
Management of patients with a newly detected adrenal mass is dictated by 1) whether there is 
evidence of associated adrenal hormone excess and 2) whether the adrenal mass is malignant 
or benign.  However, due to the limited accuracy of currently applied diagnostic tools, reaching a 
confident conclusion in regards to these two key questions is challenging for many patients with 
adrenal tumors. Patients frequently require additional immediate and/or longitudinal follow-up 
tests and visits, and invasive procedures to ascertain the precise diagnosis, such as adrenal 
biopsy or unilateral adrenalectomy, add to the burden of disease associated with adrenal 
incidentalomas.  
 
In this review, we will discuss the evidence on currently available tests to diagnose adrenal 
malignancy and review the data on urinary steroid profiling as a potential non-invasive 
diagnostic test to detect adrenocortical carcinoma (ACC) in patients with adrenal masses. 
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Diagnosis of a malignant adrenal mass 
 
Most adrenal tumors are discovered incidentally on cross-sectional imaging study performed for 
a reason other than suspected adrenal disease, e.g. unspecific abdominal pain. Imaging 
characteristics can be helpful in clarifying the nature of the adrenal mass. Pheochromocytomas 
can be taken out of the equation by highly sensitive and specific biochemical screening with 
measurement of plasma metanephrines. Doing this first, helps avoid difficulties in interpreting 
imaging findings as there is a significant overlap between pheochromocytomas and 
adrenocortical carcinomas. 
Following biochemical exclusion of a catecholamine-producing pheochromocytoma, imaging is 
the next step to detect or exclude adrenocortical malignancy. While a large tumor diameter has 
limited sensitivity and specificity for detecting an adrenocortical carcinoma 6, 7, additional 
features such as irregular borders, inhomogeneity of the mass and signs of local invasion are 
pointing to underlying adrenocortical malignancy. Tumor density on unenhanced, non-contrast 
computed tomography (CT) scans is helpful if a homogeneous density value of less than 10 
Hounsfield Units (HU) is measured in the tumor area, which invariably indicates a fat-containing 
benign adrenal tumor. Conversely, while HU values >10 are suspicious of malignancy, the 
majority of such masses eventually turn out to be benign. Similarly, on magnetic resonance 
imaging (MRI) scans, the loss of signal intensity in the so-called chemical shift analysis also 
correlates with the amount of fat contained in the adrenal tumor, with a large drop in signal 
intensity between in-phase and out-of-phase T1 sequences suggestive of a benign adrenal 
tumor. Fluorodeoxyglucose positron emission tomography (FDG-PET) has been proposed as a 
better test to diagnose a malignant adrenal mass. However, surprisingly little evidence exists on 
the diagnostic accuracy of the imaging characteristics of the commonly employed imaging 
studies, mainly due to the fact that few studies provide an optimal reference standard for 
comparison 8. While evidence for the accurate diagnostic performance of non-contrast CT HU 
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cutoff of 10 is more robust, confidence intervals of estimates for other imaging characteristics 
are wide, based on the very small sample size of studied cohorts (Table 1), and therefore their 
use, though regularly employed, is not based on high quality evidence8. 
Because of the limited specificity of imaging tests in making the diagnosis of adrenocortical 
malignancy in the setting of a high prevalence of benign adrenal tumors, the current diagnostic 
approach, which almost exclusively employs imaging tests, has a significant impact on the 
economic burden of disease. Many patients undergo either immediate additional imaging tests 
to better characterize the adrenal mass or are advised to return for imaging studies to assess 
tumor growth after an interval of 3-12 months 9. This exposes patients to radiation and increases 
health care costs, without evidence that performing multiple imaging modalities improves the 
diagnostic performance with regard to differential diagnosis between benign and malignant 
adrenal masses. Some guidelines recommend annual imaging follow for 5 years after the initial 
detection of an adrenal mass 10, 11. However, following this strategy in patients with a 
conclusively benign presentation on initial imaging, e.g. HU<10 on unenhanced CT, may result 
in significant radiation exposure and health care costs for no good reason. Therefore, the 
recently published joint clinical guidelines of the European Society for Endocrinology (ESE) and 
the European Network for the Study of Adrenal Tumors (ENSAT) have recommended that such 
patients should not undergo repeat imaging9.  
In a proportion of patients, image-guided adrenal biopsy or adrenalectomy are performed due to 
concerns about the potentially malignant nature of the incidentally detected adrenal mass. 
Adrenal biopsy is an expensive procedure with a reported rate of non-diagnostic biopsies of 
8.7% and a complication rate of 2.5% 12. In addition, adrenal biopsy has poor accuracy in 
making the diagnosis of ACC (Table 1), due to inherent difficulties for pathologists to making an 
accurate diagnosis based on very limited amounts of tissue, and therefore is not recommended 
for patients with suspected ACC 9, 13. In principle, adrenal biopsy is mainly considered in 
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patients with extra-adrenal malignancy and only, as stated by the ESE-ENSAT guidelines, if “all 
of the following criteria are fulfilled: (i) the lesion is hormonally inactive (in particular, a 
pheochromocytoma has been excluded), (ii) the lesion has not been conclusively characterized 
as benign by imaging and (iii) management would be altered by knowledge of the histology” 9.  
As adrenalectomy series suggest, one third to half of all patients undergo adrenalectomy 
unnecessarily as pathology is consistent with a benign non-functioning adrenal tumor 7, 9. This is 
likely due to underlying concern for malignancy, possibly related to larger tumor diameters.  
Indeed, despite the poor accuracy of tumor size in predicting malignancy, several published 
guidelines recommend adrenalectomy at various cutoffs of tumor size of 4 to 6 cm 10, 11, 14. 
Recent guidelines on management of adrenal tumors acknowledge the lack of evidence on the 
natural history of large apparently benign adrenal tumors to suggest a certain adrenal tumor 
cutoff for adrenalectomy but allow for a highly individualized consideration of surgery in patients 
with tumors >4 cm 9. Given the shortcomings of the currently employed imaging tests, a non-
invasive, accurate and inexpensive test to distinguish ACC from other adrenal tumors is urgently 
needed, especially in patients with large adrenal tumors and in patients with adrenal masses 
with indeterminate imaging characteristics. 
 
 
Steroid metabolite profiling 
Serum and urinary steroid analysis traditionally play an important role in the diagnosis of 
adrenal hormone excess and disorders of steroidogenesis. Around 15% of adrenal tumors 
present with either clinically overt adrenal cortex hormonal excess including overt Cushing 
syndrome, primary hyperaldosteronism and, uncommonly, hyperandrogenism 7, 15. In addition, 
up to 30-50% of patients with adrenal tumors present with evidence of mild autonomous cortisol 
excess, previously termed subclinical Cushing syndrome; the diagnosis of these patients is 
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challenging and management is usually delayed until cortisol-induced comorbidities occur 16. 
While serum steroid measurements are susceptible to differences occurring due to the diurnal 
variation in adrenal steroid secretion, 24-hour urine steroid excretion represents a more 
accurate estimate of net total adrenal hormone production 17, 18 and thus also holds diagnostic 
potential for the assessment of adrenal hormonal excess.  
 
Quantitatively, the majority of steroids excreted in the urine of adult individuals are androgens 
and glucocorticoids with a significantly lower output for mineralocorticoids and steroid 
precursors 18-20. Adrenal steroid production and metabolism are affected by gender, age and 
body mass index 18, 21, 22. Glucocorticoid metabolites are higher in men than in women and in 
obese versus lean persons 21, 22. Looking at ratios of steroids that are substrates and products, 
respectively, of a distinct steroidogenic enzyme activity allows for representative assessment of 
elements of the steroidogenic pathway, which is particularly informative in the diagnosis of 
inborn steroidogenic disorders including congenital adrenal hyperplasia. However, by reflecting 
steroidogenic output of the adrenal glands, urinary steroid profiling inherently has great potential 
in diagnosing adrenal hormone excess.  
 
 
Steroid metabolite profiling in diagnosis of ACC 
Most ACCs are large tumors at the time of initial diagnosis, and a significant number is found to 
produce adrenal hormones in excess, though this is not always clinically apparent. In general, 
the concurrent excess production of multiple steroids, in particular when including androgens, is 
considered as indicative of adrenocortical malignancy. The majority of ACCs are classified as 
non-functioning based on conventional serum steroid analysis, which mostly assesses end 
products of steroidogenesis. However, adrenocortical carcinoma cells can be considered to 
represent a more immature, dedifferentiated cell type as is typical for cancer cells. Hence, it is 
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likely that the steroidogenic pattern produced by adrenal cancer cells is characterized by large 
amounts of steroid precursors rather than end products of mature and complete 
steroidogenesis. Consistent with this assumption, a significant number of patients with ACC 
show increased production of the glucocorticoid precursor 17-hydroxyprogesterone (17OHP), 
up to half of ACC patients reported by one series 18. However, serum 17OHP only provides 
limited sensitivity for detecting enhanced steroid precursor production in adrenocortical 
carcinoma patients.  
 
Decades ago, small case series demonstrated differences in urine steroid metabolite excretion 
in some patients with ACC 23, 24. However, the first large study systematically investigating 
steroid metabolite excretion in 147 patients with confirmed adrenocortical tumors, 45 patients 
with ACC and 102 patients with benign adrenocortical carcinoma (ACA), was published in 2011 
by Arlt et al 18. In this proof-of-concept study the authors described steroid profiling by gas 
chromatography-mass spectrometry (GC-MS) combined with computational data analysis 
utilizing a machine learning-based approach 18.  The employed GC-MS steroid profiling included 
measurement of 32 adrenal steroids including metabolites of glucocorticoid, mineralocorticoid 
and androgen precursors, providing comprehensive coverage of adrenal steroid output (Figure 
1). This study revealed a distinct steroid pattern, a “malignant steroid fingerprint”, that indicated 
the presence of an adrenocortical carcinoma with 90% sensitivity and specificity. Three steroid 
metabolites were most informative in distinguishing ACC from ACA: the glucocorticoid precursor 
metabolite tetrahydro-11-deoxycortisol (THS) derived from 11-deoxycortisol and the adrenal 
androgen precursor metabolites pregnenediol (5-PD) and pregnenetriol (5-PT), derived from 
pregnenolone and 17-hydroxypregnenolone, respectively. In addition, six further steroids were 
identified on the machine learning algorithm, based on their relevance towards discriminating 
ACC from ACA: the progesterone metabolite pregnanediol (PD), the 17OHP metabolite 
pregnanetriol (PT), the 11-deoxycorticosterone metabolite tetrahydro-11-deoxycorticosterone 
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(THDOC), the corticosterone metabolite 5α-tetrahydrocortisol (5α-THA), the cortisol metabolite 
5α-tetrahydrocortisol (5α-THF), and the androgen metabolite etiocholanolone (Etio). Receiver 
operating characteristic (ROC) curve analysis demonstrated the diagnostic information of all 32 
steroids resulted in 90% sensitivity and specificity, while the 9 most informative and the top 3 
biomarker steroids provided only slightly lower diagnostic accuracies of 87.7% and 87.2%, 
respectively. Ten of the 45 ACC patients in this study had metastatic disease at the time of 24-h 
urine collection; however, their steroid profile did not differ from ACC patients who harbored the 
primary tumor only. Steroid output did not correlate with tumor size. 
In 2015, Kerkhofs et al presented their data on an independent cohort of patients with 27 ACCs 
and 125 ACAs 19.  They performed GC-MS analysis of 22 steroid metabolites but did not employ 
computational analysis to refine the diagnostic performance of the test. They identified 15 
individual steroid markers with a sensitivity of 90% or above in detecting ACC, with the 11-
deoxycortisol metabolite THS again representing the most informative markers. Other 
informative markers identified by that study included PD, PT, Etio, the major androgen 
metabolite androsterone (An) and the major glucocorticoid metabolites tetrahydrocortisol (THF) 
and tetrahydrocortisone (THE). However, specificities varied widely (2-83% for individual 
steroids). They defined a cut-off of 2.35 µmol/24h for THS excretion as 100% sensitive and 99% 
specific for the detection of ACC. However, their ACC cohort was considerably smaller and 67% 
of their ACC patients showed evidence of cortisol excess while this found in only 18% of their 
ACA patients. (Table 2). This selection bias might explain why they found the glucocorticoid 
metabolites THE and THF to be apparently distinguishing between ACC and ACA.  
A recent study by Velikanova et al. 20, carrying out GC-MS analysis of 32 steroid metabolites in 
24-h urine samples from 31 patients with ACC and 96 patients with ACA authors confirmed the 
findings reported by Arlt et al. They demonstrated that patients with ACC have significantly 
higher THS, PD, 5PT, and 5PD than patients with ACA. However, increased urinary excretion of 
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THS was demonstrated only in 74% of their patients with ACC and the authors suggested 
consideration of additional steroid parameters and ratios 20. Similar to Kerkhofs et al. they did 
not employ unbiased computational data analysis of the steroid excretion data. 
 
All three studies identified THS as the most informative steroid marker indicative of ACC. THS is 
the metabolite of 11-deoxycortisol, which is converted to cortisol by the adrenal-specific 
steroidogenic enzyme CYP11B1. Measurement of 11-deoxycortisol is not routinely used 
clinically, though recently serum results were reported in a cohort of benign adrenal tumors 25. 
Abundance of THS in patients with ACC suggests a relative deficiency of CYP11B1, and may 
be due to de-differentiation and mutational changes occurring in ACC. Similarly, the 
accumulation of the androgen precursor steroids 5PT and 5PD indicate a relative inefficiency of 
CYP17A1 (17,20 lyase) activity in converting 17-hydroxypregnenolone to the major adrenal 
androgen DHEA. Based on the available studies, it is evident that the excretion of steroid 
precursor metabolites is significantly higher in ACCs than in ACAs and we propose that this is 
due to the relative steroidogenic immaturity of the adrenocortical carcinoma cells. Steroid 
precursor metabolite excretion was equally observed both in patients with clinically evident 
adrenal hormone excess as well as in patients with clinically “endocrine inactive” ACC. 
Interestingly, steroid profiling revealed higher glucocorticoid metabolite excretion in ACA versus 
healthy volunteers, including those classified as non-functioning 17, 18, 20.  At this time, studies 
systematically exploring potential diagnostic implications of urine steroid profiling in hormonal 
excess are currently lacking. 
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CHALLENGES and FUTURE DIRECTIONS 
 
Steroid profiling has particular promise as a valuable tool for differential diagnosis in patients 
with adrenal tumors presenting with indeterminate imaging characteristics. These patients 
proceed to have additional studies, most commonly repeat CT imaging which add to the lifetime 
exposure to radiation, but also expose affected patients to cost, inconvenience, and anxiety of 
waiting another 6-12 months. Steroid profiling is an attractive noninvasive alternative which 
could help rule out ACC much earlier in the diagnostic pathway. Earlier diagnosis would allow 
for adrenalectomy without delay in patients with suspected ACC and avoid additional 
procedures and tests in patients in whom ACC is conclusively excluded. 
 
While the above initial results suggest impressive differences between 24-h urine steroid 
metabolite excretion in patients with ACC when compared to ACAs, at this time there are some 
barriers which need to be overcome before widespread use of steroid profiling as a non-invasive 
diagnostic tool in patients with adrenal tumors. All initial results are based on retrospective 
studies with still relatively small numbers of patients totaling <500 patients. Prior to 
implementation in routine clinical practice, urinary steroid metabolome profiling as a diagnostic 
tool will need to be prospectively validated in a much larger cohort of prospectively enrolled 
patients and compared to a reference standard comprising results of histopathology and clinical 
and imaging follow-up investigations. Recently, a large prospective international multi-center 
test validation study carried out with support of the European Network for Study of Adrenal 
Tumors (ENSAT) has completed after successfully recruiting more than 2000 patients with 
newly diagnosed adrenal mass. Results from this study, EURINE-ACT (Evaluation of URINE 
steroid metabolomics in the differential diagnosis of AdrenoCortical Tumors), will conclusively 
determine the diagnostic accuracy and performance of the steroid profiling in a non-selected 
cohort of patients in a “real-life” setting. 
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Even after appropriate validation is completed, there are certain challenges associated with 
universal implementation of steroid profiling into the clinical laboratory. All available current 
evidence on steroid profiling relies on measurements performed by GC-MS. However, while 
GC-MS allows the concurrent profiling of the entire steroid metabolome, the method requires 
special expertise and is only offered by a small number of institutions and laboratories. The 
method is relatively laborious and hence not cheap. However, these obstacles could be 
overcome by transfer of the steroid profiling method to the high-throughput liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) platform and these approaches have 
now been developed and are currently being investigated for their diagnostic performance. For 
widespread use of this diagnostic test it will also be critical to provide a straightforward 
diagnostic algorithm and this is likely to be achieved by the machine learning-based algorithm 
described by Arlt et al 18.  
 
Conclusion 
In conclusion, mass spectrometry-based 24-h urine steroid metabolome profiling is a highly 
promising non-invasive diagnostic tool in patients with adrenal tumors, with a diagnostic 
sensitivity and specificity that exceeds that of diagnostic imaging. While proof-of-concept and 
subsequent studies were carried out in retrospective cohorts, the outcome of a large 
prospective test validation study will be available soon. Results will determine whether steroid 
profiling can become part of widely implemented routine care in the diagnostic evaluation of 
patients with adrenal masses. 
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